CAS: 170491-63-1; Tert-Butyl 2-(Hydroxymethyl)Pyrrolidine-1-Carboxylate

相似化合物

69610-40-8 83435-58-9 148625-77-8

上下游产品

CAS号24424-99-5 二碳酸二叔丁酯 | CAS号498-63-5 吡咯烷-2-甲醇 | CAS号15761-39-4 B°C-L-脯氨酸 | CAS号861657-91-2 1-叔丁基 2-甲基 5-氧代... | CAS号201230-82-2 carbon monoxide | CAS号73286-71-2 N-B°C-2-吡咯啉 | CAS号58632-95-4 2-(叔-丁氧基碳酰胺)-2-苯乙腈 | CAS号68832-13-3 D-脯氨醇 | CAS号23356-96-9 L-脯氨醇 | CAS号56879-46-0 2-吡咯烷乙酸 | CAS号32548-24-6 1,2,5,6,7,8-hex... | CAS号174213-51-5 2-(苯氧基甲基)吡咯烷-1-... | CAS号27300-27-2 2-乙酰基-3,4,5,6(1...

📜1-Boc-四氢吡咯置于正丁基锂,四甲基乙二胺,仲丁基锂体系中,用 乙醚,正己烷 用作溶剂,化学反应 26.0H,反应生成2-羟甲基吡咯烷-1-羧酸丁酯
参考文献:(−)-Stemaphylline 的立体控制全合成
标题:(−)-Stemaphylline 的立体控制全合成
摘要:即使使用非常好的离去基团 (Cl-),容易获得的 α-硼基吡咯烷与金属类胡萝卜素的同系化也特别具有挑战性.通过进行从 Et 2 O 到 Chcl 3 的溶剂转换,中间体硼酸酯与卤化物和酯离去基团发生有效的 1,2-金属盐重排.该方法用于百部生物碱 (−)-Stemaphylline 的全合成,仅需 11 个步骤(最长的线性序列),具有高立体控制(>20:1 Dr)和 11% 的总产率.该合成还具有与含类胡萝卜素的叔胺进行后期锂化-硼化反应的特点.
Doi:10.1002/anie.201611273

专利信息

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

专利号:US-8399502-B2
优先权日:2008-09-17
标 题 :Analogs of indole-3-carbinol and their use as agents against infection
发明人：JONG LING; JIANG FAMING; LI GAOQUAN; MORTELMANS KRISTIEN
权利人:JONG LING; JIANG FAMING; LI GAOQUAN; MORTELMANS KRISTIEN; STANFORD RES INST INT
摘要:Compounds useful as antibacterial agents are provided. The compounds are analogs of indole-3-carbinol and have a backbone selected from dihydroindolo[2,3-b]carbazole, 2,2′-diindolylmethane, 2′,3-diindolylmethane, and 3,3′-diindolylmethane. The compounds are useful therapeutic and prophylactic treatment of bacterial infections in mammals. Methods of synthesis of the compounds are provided, as are pharmaceutical compositions containing the compounds.

专利号:US-8772301-B2
优先权日:2009-12-18
标题 :Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
发明人：HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D
权利人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

专利号:EP-1339677-B1
优先权日:2000-10-30
标 题 :Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
发明人：RUI YUANJIN; KUKI ATSUO; HONG YUFENG; PENG ZHENGWEI; LUTHIN DAVID ROBERT
权利人:WARNER LAMBERT CO
摘要:Novel aminoalkylpyrrolidine 5-HT₇ receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites or prodrugs thereof.

专利号:US-6228872-B1
优先权日:1998-11-12
标 题:Neurotrophic diamide and carbamate agents
发明人：DUBOWCHIK GENE M; DITTA JONATHAN L; PROVENCAL DAVID P; DENHART DEREK J
权利人:BRISTOL MYERS SQUIBB CO
摘要:The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel pyrrolidinemethyl diamide and carbamate compounds that are neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.

专利号:US-10017481-B2
优先权日:2012-03-17
标 题 :Conformationally constrained, fully synthetic macrocyclic compounds
发明人：OBRECHT DANIEL; ERMERT PHILIPP; OUMOUCH SAID; PIETTRE ARNAUD; GOSALBES JEAN-FRANÇOIS; THOMMEN MARC
权利人:POLYPHOR AG
摘要:The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.